![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2021
Naseem, Madiha; Cao, Shu; Yang, Dongyun; Millstein, Joshua; Puccini, Alberto; Loupakis, Fotios; Stintzing, Sebastian; Cremolini, Chiara; Tokunaga, Ryuma; Battaglin, Francesca; Soni, Shivani; Berger, Martin D.; Barzi, Afsaneh; Zhang, Wu; Falcone, Alfredo; Heinemann, Volker und Lenz, Heinz-Josef
(2021):
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.
In: Scientific Reports, Bd. 11, Nr. 1, 12191
2019
Suenaga, Mitsukuni; Stintzing, Sebastian; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Okazaki, Satoshi; Berger, Martin D.; Miyamoto, Yuji; Schirripa, Marta; Soni, Shivani; Barzi, Afsaneh; Heinemann, Volker und Lenz, Heinz-Josef
(2019):
Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
In: European Journal of Cancer, Bd. 107: S. 100-114
2018
Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Cremolini, Chiara; Lonardi, Sara; Bergamo, Francesca; Ning, Yang; Yamamoto, Noriko; Okazaki, Satoshi; Berger, Martin D.; Miyamoto, Yuji; Gopez, Roel; Barzi, Afsaneh; Yamaguchi, Toshiharu; Stintzing, Sebastian; Heinemann, Volker; Loupakis, Fotios; Falcone, Alfredo und Lenz, Heinz-Josef
(2018):
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
In: Pharmacogenomics Journal, Bd. 18, Nr. 5: S. 623-632
2017
Schirripa, Marta; Zhang, Wu; Heinemann, Volker; Cao, Shu; Okazaki, Satoshi; Yang, Dongyun; Loupakis, Fotios; Berger, Martin D.; Ning, Yan; Miyamoto, Yuji; Suenaga, Mitsukuni; Gopez, Roel F.; West, Jordan D.; Hanna, Diana; Barzi, Afsaneh; Falcone, Alfredo; Stintzing, Sebastian und Lenz, Heinz-Josef
(2017):
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
In: International Journal of Cancer, Bd. 141, Nr. 2: S. 383-392